EssilorLuxottica (EL) – A European Powerhouse with an unassailable Moat
This is one of those rare businesses you can buy and hold for decades without worrying about its relevance or survival. And yet, this is not a stagnant incumbent.
It’s time to revisit one of Europe’s absolute giants and largest moats.
EssilorLuxottica is one of those rare companies that seem almost impossible to disrupt. It quietly dominates the global eyewear and vision care market with a scale and integration that no rival can approach. If you wear glasses or sunglasses, chances are EssilorLuxottica made the lenses, the frame, or both, even if the logo says Ray-Ban, Oakley, Prada, or Chanel.
The group as we know it today was formed in 2018, when French lens specialist Essilor, a pioneer in optical technology and corrective lenses, merged with Italian eyewear powerhouse Luxottica, owner of iconic brands like Ray-Ban and Oakley, as well as retail banners such as Sunglass Hut, LensCrafters, and Pearle Vision. Together, they created a vertically integrated behemoth: a company that designs, manufactures, distributes, and sells eyewear at every price point, across virtually every geography, and through both owned and third-party channels.
This complete control of the value chain is at the core of EssilorLuxottica’s staggering moat. No other player in the industry comes close to its scale, distribution network, or brand portfolio. The company doesn’t just own household names like Ray-Ban and Oakley; it also holds exclusive, long-term licenses to design and produce eyewear for the world’s most prestigious fashion houses, including Chanel, Prada, Burberry, Armani, Tiffany & Co., and others. That means competitors can’t offer those brands, retailers depend on EssilorLuxottica’s products, and the company effectively sets the tone for the entire market.
The result is extraordinary pricing power, high barriers to entry, and a self-reinforcing cycle: its dominance attracts more partnerships, its scale drives better economics, and its retail presence strengthens its hold on consumers. With more than 150 brands, 18,000 company-owned stores, and hundreds of thousands of partner points of sale worldwide, EssilorLuxottica is not just a market leader; it is the market (similar to LVMH in luxury goods, but even better!).
For reference, in this highly fragmented global market, Essilor commands a 20-30% market share.
And yet, this is not a stagnant incumbent. The company continues to expand its opportunity set through innovation and strategic mergers and acquisitions. It invests heavily in R&D (around 6% of revenue) to advance lens technology and wearable eyewear, most notably through its deep partnership with Meta on Ray-Ban smart glasses, which are currently the only mass-market smart glasses product with real traction. It is also exploring new healthcare adjacencies, such as hearing solutions integrated into eyewear, and continues to strengthen its portfolio through selective acquisitions.
All this is built on a foundation of enduring demand. Vision correction is a universal need, fueled by aging populations, increased screen time, and rising wealth in emerging markets. Eyewear is also increasingly a fashion accessory, boosting replacement cycles and premiumization. These trends, combined with EssilorLuxottica’s unmatched market position, make for an unusually durable compounding machine.
Simply put, this is one of those rare businesses you can buy and hold for decades without worrying about its relevance or survival. Its moat is deep, its growth runway is long, and its ability to adapt, from lenses to luxury fashion to connected eyewear, keeps it ahead of potential disruption.
That’s why EssilorLuxottica remains a must-watch (and, at the right price, a must-own) for long-term investors.
Yet, ever since writing a deep dive into it almost a year ago, I haven’t been able to pick up shares at my desired price point, as Essilor consistently trades at a hefty (and much deserved) premium, yet I am looking to buy on some weakness.
In the meantime, a lot has happened, so it’s time for me to revisit this business to update my thesis, financial projections, and target price.
Is now a good time to add Essilor to my portfolio from my watchlist, or should we remain patient for the right entry point?
Let’s find out in this extensive thesis update on one of the world’s most powerful moats!
Welcome to InvestInsights — an independent equity research publication rooted in long-term, buy-and-hold investing, publishing actionable stock/equity research reports weekly!
📈 You’re reading my latest exclusive stock analysis. If you like this analysis, make sure to like & subscribe to receive much more like this!
If you’d like full access to this post and all my exclusive analysis & portfolio access (14% CAGR since 2022), consider becoming a paid subscriber!
Meta x Ray-Ban smart glasses – The Driver of any bull thesis!
Let’s start by addressing the most critical driver of any bullish Essilor investment thesis (since a lot has happened here over the last year), which is smart glasses in partnership with Meta, which is by far Essilor’s most significant long-term growth opportunity - and it’s massive!
You see, EssilorLuxottica and Meta together created the first smart glasses to achieve any real commercial success. Early attempts from Google, Snap, and others failed to gain traction, mainly because the products were either clunky tech prototypes or socially unacceptable to wear. The Ray-Ban and Oakley Meta smart glasses, on the other hand, have finally solved the consumer acceptance problem: they resemble iconic Ray-Bans or Oakley glasses, fit comfortably, and deliver useful hands-free features such as photo/video capture, audio, and voice-controlled AI.
The latest version of the Ray-Ban smart glasses, recently announced, now features a display, marking a significant leap in eyewear technology and making its functionality even more appealing.
Furthermore, the commercial traction is real. In Essilor’s Q2/H1 2025 disclosure, management reported that sales of Ray-Ban Meta smart glasses more than tripled year-on-year. Public reporting suggests that over 2 million pairs have been sold since the launch, which might be a relatively small number compared to the global eyewear market, but a significant leap compared to any previous smart-glasses attempt. Even more importantly, Essilor is now scaling production capacity to 10 million units per year by the end of 2026. That is a clear signal of both demand and commitment from Meta and Essilor to industrialize this category.
For Essilor, this is particularly significant, as its core eyewear market is enormous but mature. Prescription lenses and fashion frames grow at mid-single digits at best. Smart glasses are a new category with the potential for explosive growth. Market analysts expect the connected eyewear space to compound at a rate of 25–30% annually through 2030, with global shipments rising from ~2.7 million units in 2024 to nearly 19 million by 2029 (IDC).
At this time, Essilor and Meta virtually dominate this market, effectively operating a monopoly that positions them brilliantly to benefit.
Yet, even if Essilor can capture only a 20–30% market share by the end of the decade, this would still be a multi-billion-dollar opportunity. Of course, that would still not eclipse the company’s €25 billion core business, but it would be a meaningful new growth engine.
And the upside could be much larger if Mark Zuckerberg’s bet plays out. He has repeatedly said he sees smart glasses as the next major computing platform, potentially replacing or supplementing smartphones over time. If that happened, it would be a once-in-a-generation market expansion for Essilor:
Glasses are already one of the few wearables consumers accept on their faces.
If the next “iPhone moment” happens in glasses, almost all of those devices will need optical expertise, fashionable frames, and mass manufacturing, areas where Essilor is unrivaled.
The global smartphone market sells over 1.2 billion units annually. Even capturing a fraction of that would dwarf today’s eyewear industry and could multiply Essilor’s total addressable market.
For now, this is optionality rather than a base case. The technology still faces hurdles, including all-day battery life, bright and lightweight displays, privacy acceptance, and a true “killer app” beyond photos and notifications. Most analysts don’t expect mainstream AR glasses to arrive before the early to mid-2030s. And even then, adoption will likely be gradual, with glasses complementing phones first rather than replacing them outright.
Still, Essilor is perfectly positioned. Big tech is discovering that creating attractive, comfortable, prescription-ready eyewear is far more challenging than building a phone or VR headset. Meta’s partnership with Essilor shows this:
Optics & medical complexity: Essilor has decades of lens IP, fitting standards, and regulatory expertise that Meta lacks.
Fashion credibility: Ray-Ban gives instant cultural acceptance that a “Meta Glass” brand could not replicate.
Industrial & retail scale: Essilor can produce millions of units and place them in its own stores (Sunglass Hut, LensCrafters) and through hundreds of thousands of opticians, something Meta would need years and billions to build.
The alliance is also financially reinforced. Meta has already invested approximately $3.5 billion to acquire a roughly 3% stake in EssilorLuxottica and holds an option to increase this to 5% in the coming years. That kind of capital commitment signals that Meta sees Essilor as its long-term hardware partner rather than just a contract manufacturer. Combined with the extended supply and development agreements that run well into the next decade, this makes the relationship highly beneficial to Essilor in the medium term and very sticky.
Could Meta eventually bring eyewear in-house if smart glasses become the next iPhone? Possibly. Tech companies crave control and margins, but replicating Essilor’s optical IP, global manufacturing network, and Ray-Ban’s brand power would require an enormous amount of time and capital. For at least the next 5–10 years, the partnership looks secure and strategically indispensable.
Long story short, smart glasses won’t soon overtake Essilor’s core business, but they represent a serious, high-upside third growth engine. In a conservative scenario, they could add a few billion in revenue and margin expansion by the end of the decade. In an aggressive scenario, assuming that smart glasses truly become the next personal computing platform, Essilor’s addressable market could multiply, and its role as the go-to partner for big tech could become transformative.
Essilor is most certainly the best-positioned, and I like this current growth engine and the promise of the long-term opportunity, especially layered on top of an already dominant, defensive, cash-rich eyewear empire.
On that note, let’s review its performance and financials.
A Top-line Performance update + growth drivers
It is worth noting that Essilor, being a European company (which isn’t required to report quarterly), reports its full earnings every six months. It released its latest financial results back in late July, which were its 1H25 results, and it delivered strong top-line growth but showed some weakness on the bottom line amid a less favorable product mix, which did send shares down a few percentage points in the following trading session.
Yet, since reporting earnings, shares have performed exceptionally well amid significant new product announcements and positive macroeconomic developments, with shares gaining 15% since then, and now up 29% over the last twelve months.
Let me take you through the numbers.
Starting at the top, Essilor reported total H1 revenue of €14 billion, up 7.3% YoY in constant currency, with over 7% growth in both Q1 and Q2. For Essilor, this is excellent growth, accelerating from last year and sitting in the low-to-high single digits, driven by outstanding growth across all regions and healthy demand despite some macro headwinds and price hikes to offset price pressure.
Yet, we also have to note that this included a two percentage point contribution from the acquisitions of Heidelberg Engineering and Supreme, so organic growth was closer to 5%, which is about what you would expect from Essilor, operating in such a mature industry.
Nevertheless, this performance really shows the resilience of the Essilor business model.
EssilorLuxottica is one of the most defensive consumer-facing businesses you can own. Vision correction is an essential, recurring need driven by aging populations, increased screen time, and global trends toward myopia, rather than discretionary spending. Most people replace their prescription lenses on a predictable cycle, and in many markets, purchases are partially reimbursed or backed by insurance, which keeps demand resilient even when the economy weakens.
The company’s exposure to fashion frames adds some discretionary sensitivity, but glasses remain a functional product first and a visible personal accessory second, so demand tends to hold up better than in other luxury categories.
Its vertically integrated model also gives it exceptional pricing power and cost control. Because it designs, manufactures, distributes, and sells its own products, EssilorLuxottica has repeatedly passed on higher input and labor costs through price increases and mix upgrades, protecting margins during inflationary periods. Geographic and channel diversification further smooths performance; the company balances exposure across North America, Europe, the Asia-Pacific region, and Latin America, and sells through both its own stores and third-party retailers.
While a severe recession can dent traffic in Sunglass Hut or reduce appetite for premium upgrades, the core prescription lens and optical care business is largely insensitive to economic cycles. Combined with its ability to offset cost inflation, this makes EssilorLuxottica a fundamentally anti-cyclical and highly inflation-resistant compounder.
These natural benefits make it an exceptionally reliable performer and a sound investment – a true cornerstone in any portfolio.
Delving a little more into the H1 regional performance, let’s start with its largest region by revenue: North America. This was actually the slowest-growing region so far in 2025, with revenue growing 4.2% in Q1 and accelerating to 5.5% in Q2. However, concerning the underlying market conditions, this was still relatively healthy growth, especially considering that Essilor implemented a single-digit price increase across its portfolio. Notably, the demand impact was negligible, once again highlighting its resilience.
That brings me to the fastest-growing and second-largest region, Europe, where H2 revenue grew 9.5%. Remarkably, Essilor has now delivered four straight years of growth in Europe, delivering 9.5% growth in H2, despite lapping 8% growth in 2023 and 2024.
In particular, Essilor’s “sun” part of the business performed very well, amid a higher-than-average amount of sunshine this summer in the EMEA region, resulting in double-digit growth in Spain, France, Turkey, and high-single-digit growth in the U.K. The overall result was 20% YoY growth in its top 20 sun countries in Europe, which brings in 15% of revenue, so this helped its performance greatly!
Moving on to Asia, revenue here grew 8% YoY at constant currency, driven by healthy growth in both professional and DTC. To quote management, “From a country standpoint, Japan and Korea delivered double-digit growth. India and Southeast Asia were in the mid-single-digit territory, while China and Australia delivered a low-single-digit quarter for Q2.”
Finally, there is LatAm, where Essilor is showing excellent traction, with consecutive growth for 4.5 years and a 9% increase in revenue in the first half of the year.
So, it’s safe to say that Essilor is seeing healthy demand and growth across all regions, despite price hikes and macroeconomic concerns.
In terms of broader growth drivers, it is worth noting the strong performance in smart glasses, even though this represents a tiny portion of total revenue.
So far in 2025, Essilor is seeing excellent demand for its Ray-Ban Meta and Oakley Meta smart glasses. Ray-Ban Meta sales grew more than 200% YoY, helped by the rollout of new AI-driven features such as real-time translation and the adoption of transition and prescription lenses.
However, apart from its smart glasses partnership with Meta, which I have already addressed extensively, another huge potential growth lever and driver for Essilor today is MedTech wearables.
You see, EssilorLuxottica is quietly repositioning itself to become a healthcare technology powerhouse, not just a vision and fashion giant. By moving beyond traditional eyewear into medical diagnostics, treatment, and sensor-enabled glasses, management is opening up entirely new markets while deepening the company’s competitive moat.
A key step was the acquisition of Optegra Eye Clinics, a leading network of specialist ophthalmology centers focused on diagnostics, laser surgery, and advanced eye care. This deal advances Essilor’s presence throughout the entire eye-care journey, from retail optometry and lenses to diagnostics, therapy, and even surgery.
Most importantly, Optegra’s expertise will support pilot programs in Essilor’s global retail network, enabling stores like LensCrafters or Sunglass Hut to evolve from simple eyewear outlets into vision-health hubs that offer screenings and referrals for treatment.
Ultimately, Essilor is developing a long-term vision in which glasses become true medical and health data platforms. Management has been explicit:
“The future of glasses goes far beyond vision correction. They will become innovative, powerful, AI-enabled platforms that support human performance and healthcare at various levels… Our ambition is to become the world’s leading processor of healthcare metrics using a network of smart eyewear equipped with sensors and cameras to collect and analyze information.”
Crucially, with half a billion consumer touchpoints annually through its retail network and brand reach, Essilor sits at the center of an unparalleled data funnel. Glasses already have physical contact with the body and a clear line of sight to the eye, which is a uniquely rich source of health data (vascular and neural signals can be detected through the retina). This positions Essilor to innovate in diagnostics, early disease detection, and monitoring of conditions such as neurodegenerative or cardiovascular disease, areas where the eye is an emerging biomarker.
Some of this vision is already materializing in MedTech wearables. The most concrete example is Nuance Audio, Essilor’s first hearing-enhanced eyewear platform. Nuance integrates nearly invisible hearing aids into stylish prescription glasses. The rollout is accelerating, now available in more than 10,000 doors across North America and Europe, spanning both optical and hearing-care channels. Feedback has been overwhelmingly positive, not only on the hearing technology itself but also on the seamless integration with prescription lenses, with over 80% of customers opting for corrective lenses in conjunction with the hearing solution.
Hearing aids alone represent a massive adjacent market, as more than 1.6 billion people worldwide have some degree of hearing loss, yet penetration remains low due to stigma, cost, and usability. By embedding hearing assistance into a familiar, fashionable form factor, Essilor has a chance to unlock a reluctant customer base and meaningfully expand its total addressable market.
Ultimately, the bigger vision is that this is only the beginning. Essilor aims to transform glasses into multifunctional health wearables: devices that correct vision, improve hearing, and potentially monitor vital signs or detect early disease signals, all while resembling ordinary eyewear.
It’s early, and this segment is still immaterial to revenue today, but the strategic logic is powerful:
The hearing-aid opportunity alone is a multi-billion-dollar opportunity.
Eye health diagnostics and early detection represent an even larger potential TAM as populations age.
Essilor’s unique position, with a massive retail footprint, consumer trust, optical IP, and data access, gives it a head start no other company has.
For investors, the takeaway is similar to the smart glasses story: treat MedTech wearables as a long-term call option layered on top of an already defensible, cash-generating eyewear empire. It won’t drive the numbers in the next couple of years, but it could become a meaningful third growth pillar over the next decade if adoption sticks.
Strategically, this doesn’t just add a new revenue stream; it expands Essilor’s addressable market from a mature € 100 billion eyewear segment into the far larger global eye-health and medtech space, while making its vertical integration even harder to replicate.
On that note, let’s move to the bottom-line results.
Want more out of your subscription? Even more content like this weekly?
Consider InvestInsights PRO - $7.50/month ($70/annually)
This gets you:
A guaranteed 6+ stock analyses every month (roughly 2-4 paid-exclusive).
Full insight into my own portfolio (14% return CAGR since 2022).
Instant transaction alerts anytime I make a move (Fully transparent).
A complete overview of all my target prices and ratings (online available).
Want to keep reading? You will get full access to this EssilorLuxottica analysis!
Essilor’s margins & cash flows
The first half of 2025 wasn’t an easy one for Essilor, as it faced inflationary headwinds, primarily due to U.S. tariffs. Considering this backdrop, the bottom-line result was quite impressive, with the company essentially maintaining margins while still investing heavily in the business.
